N-803 in Patients With Progressive Synovial Sarcoma and Myxoid/Round Cell Liposarcoma Previously Treated With Adoptive Cellular Therapy
NCT07261657 is a phase early 1 interventional trial sponsored by Seth Pollack. As of 21 Nov 2026, it is recruiting participants. It studies Nogapendekin alfa inbakicept in Myxoid Liposarcoma, Round Cell Liposarcoma and 1 more condition. The registry lists an enrollment of 8 participants at 1 site in 1 country. The registry lists a start date of 13 Apr 2026 and a primary completion date of 2 Sept 2030. One of its registered investigators has a FindMyKOL profile.
Key facts
Registry attributes as recorded on the ClinicalTrials.gov study record.
| Field | Value |
|---|---|
| Registry ID | NCT07261657 |
| Status | Recruiting |
| Phase | Phase Early 1 |
| Study type | Interventional trial |
| Lead sponsor | Seth Pollack |
| Enrollment | 8 |
| Registered sites | 1 |
| Countries | 1 |
| Conditions | Myxoid Liposarcoma, Round Cell Liposarcoma and Synovial Sarcoma |
| Drugs | Nogapendekin alfa inbakicept |
| Start | 13 Apr 2026 |
| Primary completion | 2 Sept 2030 |
| Study completion | 2 Sept 2032 |
| Last update posted | 27 Aug 2026 |
Registered summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Northwestern University
Chicago
Seth M. Pollack, MDRecruiting
United States, by state
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Questions about NCT07261657
Each answer restates registry values shown on this page.
What is NCT07261657?
NCT07261657 is a phase early 1 interventional trial sponsored by Seth Pollack. It studies Nogapendekin alfa inbakicept in Myxoid Liposarcoma, Round Cell Liposarcoma and 1 more condition.
Is NCT07261657 recruiting?
As of 21 Nov 2026, it is recruiting participants. 1 of its 1 sites list their own status as recruiting.
Who leads NCT07261657?
The registry names Seth M Pollack, MD (principal investigator, Northwestern University) as the overall official.
Where does NCT07261657 run?
The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.
Which drugs does NCT07261657 study?
The registered drug and biological interventions are Nogapendekin alfa inbakicept.
When is NCT07261657 expected to complete?
The registry lists a primary completion date of 2 Sept 2030 and a study completion date of 2 Sept 2032. The sponsor last updated the record on 27 Aug 2026.
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.